BACKGROUND: Biennial screening mammography retains most of the benefits of annual breast cancer screening with reduced harms. Whether screening guidelines based on race/ethnicity and age would be more effective than age-based guidelines is unknown. METHODS: Mammography data from the Breast Cancer Surveillance Consortium were linked to pathology and tumor databases. The authors identified women aged 40 to 74 years who underwent annual, biennial, or triennial screening mammography between 1994 and 2008. Logistic regression was used to estimate adjusted odds ratios (OR) and 95% confidence intervals (95% CI) of adverse tumor characteristics among 14,396 incident breast cancer cases and 10-year cumulative risks of false-positive recall and biopsy recommendation among 1,276,312 noncases. RESULTS: No increased risk of adverse tumor characteristics associated with biennial versus annual screening were noted in white women, black women, Hispanic women aged 40 to 49 years, or Asian women aged 50 to 74 years. Hispanic women aged 50 to 74 years who screened biennially versus annually were found to have an increased risk of late-stage disease (OR, 1.6; 95% CI, 1.0-2.5) and large tumors (OR, 1.6; 95% CI, 1.1-2.4). Asian women aged 40 to 49 years who underwent biennial screening had an elevated risk of positive lymph nodes (OR, 3.1; 95% CI, 1.3-7.1). No elevated risks were associated with triennial versus biennial screening. Cumulative false-positive risks decreased markedly with a longer screening interval. CONCLUSIONS: The authors found limited evidence of elevated risks of adverse tumor characteristics with biennial versus annual screening, whereas cumulative false-positive risks were lower. However, elevated risks of late-stage disease in Hispanic women and lymph node-positive disease in younger Asian women who screened less often than annually warrant consideration and replication.
BACKGROUND: Biennial screening mammography retains most of the benefits of annual breast cancer screening with reduced harms. Whether screening guidelines based on race/ethnicity and age would be more effective than age-based guidelines is unknown. METHODS: Mammography data from the Breast Cancer Surveillance Consortium were linked to pathology and tumor databases. The authors identified women aged 40 to 74 years who underwent annual, biennial, or triennial screening mammography between 1994 and 2008. Logistic regression was used to estimate adjusted odds ratios (OR) and 95% confidence intervals (95% CI) of adverse tumor characteristics among 14,396 incident breast cancer cases and 10-year cumulative risks of false-positive recall and biopsy recommendation among 1,276,312 noncases. RESULTS: No increased risk of adverse tumor characteristics associated with biennial versus annual screening were noted in white women, black women, Hispanic women aged 40 to 49 years, or Asian women aged 50 to 74 years. Hispanic women aged 50 to 74 years who screened biennially versus annually were found to have an increased risk of late-stage disease (OR, 1.6; 95% CI, 1.0-2.5) and large tumors (OR, 1.6; 95% CI, 1.1-2.4). Asian women aged 40 to 49 years who underwent biennial screening had an elevated risk of positive lymph nodes (OR, 3.1; 95% CI, 1.3-7.1). No elevated risks were associated with triennial versus biennial screening. Cumulative false-positive risks decreased markedly with a longer screening interval. CONCLUSIONS: The authors found limited evidence of elevated risks of adverse tumor characteristics with biennial versus annual screening, whereas cumulative false-positive risks were lower. However, elevated risks of late-stage disease in Hispanic women and lymph node-positive disease in younger Asian women who screened less often than annually warrant consideration and replication.
Authors: Christina A Clarke; Theresa H M Keegan; Juan Yang; David J Press; Allison W Kurian; Anish H Patel; James V Lacey Journal: J Natl Cancer Inst Date: 2012-07-05 Impact factor: 13.506
Authors: R Ballard-Barbash; S H Taplin; B C Yankaskas; V L Ernster; R D Rosenberg; P A Carney; W E Barlow; B M Geller; K Kerlikowske; B K Edwards; C F Lynch; N Urban; C A Chrvala; C R Key; S P Poplack; J K Worden; L G Kessler Journal: AJR Am J Roentgenol Date: 1997-10 Impact factor: 3.959
Authors: Rowan T Chlebowski; Zhao Chen; Garnet L Anderson; Thomas Rohan; Aaron Aragaki; Dorothy Lane; Nancy C Dolan; Electra D Paskett; Anne McTiernan; F Alan Hubbell; Lucile L Adams-Campbell; Ross Prentice Journal: J Natl Cancer Inst Date: 2005-03-16 Impact factor: 13.506
Authors: Emily White; Diana L Miglioretti; Bonnie C Yankaskas; Berta M Geller; Robert D Rosenberg; Karla Kerlikowske; Laura Saba; Pamela M Vacek; Patricia A Carney; Diana S M Buist; Nina Oestreicher; William Barlow; Rachel Ballard-Barbash; Stephen H Taplin Journal: J Natl Cancer Inst Date: 2004-12-15 Impact factor: 13.506
Authors: E S Wai; Y D'yachkova; I A Olivotto; S Tyldesley; N Phillips; L J Warren; A J Coldman Journal: Br J Cancer Date: 2005-03-14 Impact factor: 7.640
Authors: Heidi D Nelson; Ellen S O'Meara; Karla Kerlikowske; Steven Balch; Diana Miglioretti Journal: Ann Intern Med Date: 2016-01-12 Impact factor: 25.391
Authors: Anne Marie McCarthy; Philip Yamartino; Jianing Yang; Mirar Bristol; Emily F Conant; Katrina Armstrong Journal: Med Care Date: 2015-08 Impact factor: 2.983
Authors: Katja Kemp Jacobsen; Linn Abraham; Diana S M Buist; Rebecca A Hubbard; Ellen S O'Meara; Brian L Sprague; Karla Kerlikowske; Ilse Vejborg; My Von Euler-Chelpin; Sisse Helle Njor Journal: Cancer Epidemiol Date: 2015-05-23 Impact factor: 2.984
Authors: Karla Kerlikowske; Shuai Chen; Marzieh K Golmakani; Brian L Sprague; Jeffrey A Tice; Anna N A Tosteson; Garth H Rauscher; Louise M Henderson; Diana S M Buist; Janie M Lee; Charlotte C Gard; Diana L Miglioretti Journal: J Natl Cancer Inst Date: 2022-05-09 Impact factor: 11.816
Authors: Diana L Miglioretti; Weiwei Zhu; Karla Kerlikowske; Brian L Sprague; Tracy Onega; Diana S M Buist; Louise M Henderson; Robert A Smith Journal: JAMA Oncol Date: 2015-11 Impact factor: 31.777
Authors: Carlos Canelo-Aybar; Margarita Posso; Nadia Montero; Ivan Solà; Zuleika Saz-Parkinson; Stephen W Duffy; Markus Follmann; Axel Gräwingholt; Paolo Giorgi Rossi; Pablo Alonso-Coello Journal: Br J Cancer Date: 2021-11-26 Impact factor: 9.075
Authors: Thao-Quyen H Ho; Michael C S Bissell; Karla Kerlikowske; Rebecca A Hubbard; Brian L Sprague; Christoph I Lee; Jeffrey A Tice; Anna N A Tosteson; Diana L Miglioretti Journal: JAMA Netw Open Date: 2022-03-01